Cargando…
Tiotropium Bromide: An Update
Tiotropium bromide is a once-daily inhaled anticholinergic bronchodilator. It works by blocking the muscarinic receptors in airway smooth muscle. Tiotropium has a wide therapeutic margin, due to its poor gastrointestinal absorption and its very low systemic bioavailability. The drug is mainly indica...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684714/ https://www.ncbi.nlm.nih.gov/pubmed/19461900 http://dx.doi.org/10.2174/1874306400903010043 |
_version_ | 1782167260008284160 |
---|---|
author | Heredia, Josep Lluis |
author_facet | Heredia, Josep Lluis |
author_sort | Heredia, Josep Lluis |
collection | PubMed |
description | Tiotropium bromide is a once-daily inhaled anticholinergic bronchodilator. It works by blocking the muscarinic receptors in airway smooth muscle. Tiotropium has a wide therapeutic margin, due to its poor gastrointestinal absorption and its very low systemic bioavailability. The drug is mainly indicated in COPD patients. Clinically relevant outcomes such as significant improvements in spirometry, hyperinflation, dyspnea, heath status, acute exacerbations and mortality have been consistently observed in tiotropium clinical trials, and the drug has been shown to reduce the risk of mortality due to cardiac-vascular disease and respiratory failure. The main side effect reported is dryness of the mouth. Some subgroups of asthmatics also seem to respond to anticholinergic drugs: among them, those with the Arg/Arg genotype for the β2-adrenergic receptor and those with a high percentage of neutrophils in sputum. |
format | Text |
id | pubmed-2684714 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Bentham Open |
record_format | MEDLINE/PubMed |
spelling | pubmed-26847142009-05-21 Tiotropium Bromide: An Update Heredia, Josep Lluis Open Respir Med J Article Tiotropium bromide is a once-daily inhaled anticholinergic bronchodilator. It works by blocking the muscarinic receptors in airway smooth muscle. Tiotropium has a wide therapeutic margin, due to its poor gastrointestinal absorption and its very low systemic bioavailability. The drug is mainly indicated in COPD patients. Clinically relevant outcomes such as significant improvements in spirometry, hyperinflation, dyspnea, heath status, acute exacerbations and mortality have been consistently observed in tiotropium clinical trials, and the drug has been shown to reduce the risk of mortality due to cardiac-vascular disease and respiratory failure. The main side effect reported is dryness of the mouth. Some subgroups of asthmatics also seem to respond to anticholinergic drugs: among them, those with the Arg/Arg genotype for the β2-adrenergic receptor and those with a high percentage of neutrophils in sputum. Bentham Open 2009-04-14 /pmc/articles/PMC2684714/ /pubmed/19461900 http://dx.doi.org/10.2174/1874306400903010043 Text en © Josep Lluis Heredia; Licensee Bentham Open. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Heredia, Josep Lluis Tiotropium Bromide: An Update |
title | Tiotropium Bromide: An Update |
title_full | Tiotropium Bromide: An Update |
title_fullStr | Tiotropium Bromide: An Update |
title_full_unstemmed | Tiotropium Bromide: An Update |
title_short | Tiotropium Bromide: An Update |
title_sort | tiotropium bromide: an update |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684714/ https://www.ncbi.nlm.nih.gov/pubmed/19461900 http://dx.doi.org/10.2174/1874306400903010043 |
work_keys_str_mv | AT herediajoseplluis tiotropiumbromideanupdate |